Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of intermittent fasting on quality of life tolerance of chemotherapy in patients with gynecological cancers: study protocol of a randomized-controlled multi-center trial.
Schmidt MW, Brenner W, Gebhard S, Schmidt M, Singer S, Weidenbach L, Hahn H, Puzankova D, Blau-Schneider B, Lehnert A, Battista MJ, Almstedt K, Lütkemeyer A, Radsak MP, Mähringer-Kunz A, Krajnak S, Linz VC, Schwab R, Gabriel B, Hasenburg A, Anic K. Schmidt MW, et al. Among authors: krajnak s. Front Oncol. 2023 Jul 19;13:1222573. doi: 10.3389/fonc.2023.1222573. eCollection 2023. Front Oncol. 2023. PMID: 37538111 Free PMC article.
A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
Heimes AS, Schmidt M, Jäkel J, Almstedt K, Gebhard S, Weyer-Eiberich V, Elger T, Krajnak S, Brenner W, Hasenburg A, Battista MJ. Heimes AS, et al. Among authors: krajnak s. Arch Gynecol Obstet. 2019 Jan;299(1):239-246. doi: 10.1007/s00404-018-4941-z. Epub 2018 Oct 24. Arch Gynecol Obstet. 2019. PMID: 30357498
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
Almstedt K, Mendoza S, Otto M, Battista MJ, Steetskamp J, Heimes AS, Krajnak S, Poplawski A, Gerhold-Ay A, Hasenburg A, Denkert C, Schmidt M. Almstedt K, et al. Among authors: krajnak s. Breast Cancer Res Treat. 2020 Jul;182(1):137-146. doi: 10.1007/s10549-020-05688-1. Epub 2020 May 20. Breast Cancer Res Treat. 2020. PMID: 32436145 Free PMC article.
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.
Krajnak S, Schnatz C, Almstedt K, Brenner W, Haertner F, Heimes AS, Lebrecht A, Makris GM, Schwab R, Hasenburg A, Schmidt M, Battista MJ. Krajnak S, et al. Breast Cancer Res Treat. 2020 Jul;182(2):389-399. doi: 10.1007/s10549-020-05711-5. Epub 2020 Jun 3. Breast Cancer Res Treat. 2020. PMID: 32495001 Free PMC article.
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.
Krajnak S, Decker T, Schollenberger L, Rosé C, Ruckes C, Fehm T, Thomssen C, Harbeck N, Schmidt M. Krajnak S, et al. J Cancer Res Clin Oncol. 2021 Nov;147(11):3391-3400. doi: 10.1007/s00432-021-03599-2. Epub 2021 Mar 20. J Cancer Res Clin Oncol. 2021. PMID: 33743073 Free PMC article. Clinical Trial.
39 results